Your browser is no longer supported. Please, upgrade your browser.
ILMN Illumina, Inc. daily Stock Chart
Illumina, Inc.
IndexS&P 500 P/E60.46 EPS (ttm)5.39 Insider Own0.50% Shs Outstand147.87M Perf Week-0.40%
Market Cap48.20B Forward P/E53.18 EPS next Y6.13 Insider Trans-9.41% Shs Float146.28M Perf Month4.77%
Income798.00M PEG2.86 EPS next Q1.26 Inst Own91.90% Short Float1.40% Perf Quarter21.51%
Sales3.10B P/S15.53 EPS this Y89.40% Inst Trans-0.66% Short Ratio2.28 Perf Half Y43.88%
Book/sh22.16 P/B14.71 EPS next Y12.39% ROA11.90% Target Price334.73 Perf Year72.19%
Cash/sh16.99 P/C19.19 EPS next 5Y21.11% ROE21.80% 52W Range189.15 - 341.08 Perf YTD49.20%
Dividend- P/FCF64.10 EPS past 5Y39.20% ROI9.90% 52W High-4.42% Beta0.94
Dividend %- Quick Ratio2.40 Sales past 5Y19.10% Gross Margin68.90% 52W Low72.34% ATR7.72
Employees6200 Current Ratio2.70 Sales Q/Q25.40% Oper. Margin27.60% RSI (14)56.80 Volatility1.61% 2.55%
OptionableYes Debt/Eq0.41 EPS Q/Q62.20% Profit Margin20.90% Rel Volume1.31 Prev Close325.88
ShortableYes LT Debt/Eq0.22 EarningsJul 30 AMC Payout0.00% Avg Volume897.58K Price325.99
Recom1.90 SMA200.93% SMA507.67% SMA20029.09% Volume1,172,364 Change0.03%
Aug-07-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-31-18Reiterated Canaccord Genuity Buy $330 → $340
Feb-05-18Upgrade Citigroup Neutral → Buy
Jan-31-18Upgrade First Analysis Sec Equal-Weight → Overweight $277
Jan-05-18Initiated BTIG Research Neutral
Jan-05-18Downgrade William Blair Outperform → Mkt Perform
Jan-02-18Upgrade Wells Fargo Market Perform → Outperform
Oct-25-17Upgrade Robert W. Baird Neutral → Outperform $184 → $228
Oct-23-17Upgrade Janney Sell → Neutral
Oct-23-17Upgrade Deutsche Bank Hold → Buy $195 → $250
Sep-26-17Resumed Goldman Neutral $200
Aug-07-17Upgrade Canaccord Genuity Hold → Buy $170 → $215
Aug-02-17Upgrade First Analysis Sec Underweight → Equal-Weight
Apr-26-17Reiterated Cantor Fitzgerald Neutral $155 → $170
Mar-20-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-01-17Reiterated UBS Buy $180 → $185
Jan-18-17Initiated Deutsche Bank Hold $160
Jan-10-17Upgrade BofA/Merrill Neutral → Buy
Jan-06-17Upgrade CL King Neutral → Buy
Dec-07-16Reiterated Morgan Stanley Underweight $115 → $100
Aug-20-18 11:10AM  Roche's Lung Cancer Drug Alecensa Gets Approval in China Zacks
08:45AM highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International Zacks
Aug-17-18 09:44AM  4 Winning Stocks With Solid Efficiency Level Zacks
09:12AM  Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA Zacks
Aug-16-18 08:28PM  Illumina Announces Pricing of Convertible Senior Notes Business Wire
Aug-15-18 04:15PM  Illumina to Offer $650 Million Convertible Senior Notes Business Wire
Aug-14-18 06:13PM  Will This Biotech Stock Join the $1,000 Human Genome Club in Early 2019? Motley Fool
08:33AM  Can Illumina (ILMN) Stock Continue to Grow Earnings? Zacks
Aug-10-18 08:07PM  Here's Why CareDx Jumped 13.5% Today Motley Fool
06:45PM  Why Illumina, Inc. Stock Popped 16.1% in July Motley Fool
Aug-09-18 11:48AM  PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y Zacks
09:20AM  OPKO Health (OPK) Earnings & Revenues Beat Estimates in Q2 Zacks
09:10AM  Wright Medical (WMGI) Beats on Q2 Earnings, Raises '18 View Zacks
Aug-08-18 01:01PM  IBD 50 Growth Stocks To Watch Investor's Business Daily
09:30AM  CBM vs. ILMN: Which Stock Should Value Investors Buy Now? Zacks
08:34AM  Inogen (INGN) Beats on Q2 Earnings, Lifts '18 Sales Guidance Zacks
07:54AM  Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View Zacks
Aug-07-18 11:43AM  Market, Policy Trends Are Shifting In Illumina's Favor, Morgan Stanley Says In Upgrade Benzinga
10:24AM  DENTSPLY (XRAY) Beats on Q2 Earnings, Lowers 2018 Guidance Zacks
08:57AM  Dow Jones Leads Stocks Higher As Disney Jumps, Global Markets Rally Investor's Business Daily
08:50AM  Luminex (LMNX) Misses on Earnings in Q2, Margins Contract Zacks
Aug-06-18 04:00PM  This stock sector most often beats analysts estimates MarketWatch
02:04PM  Illumina CEO on the growth of DNA sequencing CNBC Videos
09:27AM  Allscripts (MDRX) Q2 Earnings In Line, Revenues Top Estimates Zacks
08:52AM  Cardinal Health (CAH) Surpasses Earnings Estimates in Q4 Zacks
08:20AM  Detailed Research: Economic Perspectives on Allete, Sterling Construction, Illumina, PROS, Altra Industrial Motion, and Pacific Biosciences of California What Drives Growth in Today's Competitive Landscape GlobeNewswire
Aug-03-18 05:36PM  Quality Systems (QSII) Q1 Earnings & Revenues Beat Estimates Zacks
04:58PM  Cerner (CERN) Beats Q2 Earnings Estimates, Bookings Rise Y/Y Zacks
12:35PM  8 Bargain Stocks With Big Upside Potential Investopedia
09:58AM  Pacific Biosciences (PACB) Loss In Line With Estimates in Q2 Zacks
09:50AM  DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View Zacks
08:48AM  Integer Holdings (ITGR) Beats on Q2 Earnings, '18 View Solid Zacks
07:31AM  The Zacks Analyst Blog Highlights: Microsoft, Micron,, Illumina and Activision Zacks
Aug-02-18 02:07PM  CONMED (CNMD) Beats on Q2 Earnings, Raises 2018 Guidance Zacks
12:21PM  DaVita (DVA) Beats Earnings and Revenue Estimates in Q2 Zacks
11:38AM  Becton, Dickinson (BDX) Earnings and Revenues Beat in Q3 Zacks
10:45AM  Express Scripts (ESRX) Q2 Earnings Beat, Network Claims Fall Zacks
10:42AM  AmerisourceBergen (ABC) Beats on Q3 Earnings & Revenues Zacks
09:59AM  Tariff Woes Haunt Wall Street: Take Refuge in These 5 Stocks Zacks
08:48AM  Illumina, Whirlpool and Square highlighted as Zacks Bull and Bear of the Day Zacks
Aug-01-18 09:03AM  Fresenius Medical (FMS) Misses Q2 Earnings & Sales Estimates Zacks
06:01AM  Here's What You Can Expect for Illumina After Its Fantastic Q2 Earnings Results Motley Fool
Jul-31-18 07:24PM  Edited Transcript of ILMN earnings conference call or presentation 30-Jul-18 9:00pm GMT Thomson Reuters StreetEvents +12.14%
06:14PM  After the Bell: Dow Jumps 108 Points to Make July Best Month Since January
05:26PM  What Happened in the Stock Market Today Motley Fool
03:52PM  Biotech ETFs Rally as Illumina Tops Q2 Expectations ETF Trends
03:48PM  Why Illumina Inc. Stock Jumped Today Motley Fool
03:13PM  Luna DNA Is About to Revolutionize Medicine -- and It'll Pay You to Help Motley Fool
12:37PM  Illumina's stock runs up toward record high as earnings beat prompts price target boosts MarketWatch
12:08PM  Ecolab (ECL) Q2 Earnings In Line, Revenues Beat Estimates Zacks
09:30AM  Is Illumina (ILMN) Outperforming Other Medical Stocks This Year? Zacks
09:22AM  Stocks to Watch: P&G, Pfizer, Qualcomm, CBS, Chipotle, Archer-Daniels-Midland, Illumina The Wall Street Journal
09:14AM  Illumina (ILMN) Beats on Q2 Earnings, Lifts '18 Guidance Zacks
08:59AM  Illumina, Inc. (ILMN) Q2 2018 Earnings Conference Call Transcript Motley Fool
08:50AM  athenahealth (ATHN) Beats on Q2 Earnings, Raises '19 View Zacks
08:00AM  Todays Research Reports on Stocks to Watch: Illumina and Okta ACCESSWIRE
Jul-30-18 05:58PM  After-hours buzz: AKS, TXRH & more CNBC
05:57PM  Illumina Inc. Delivers Another Outstanding Quarter Helped by Strong Consumables Growth Motley Fool
04:19PM  Illumina shares rally on company earnings, revenue outlook MarketWatch
04:17PM  Illumina: 2Q Earnings Snapshot Associated Press
04:05PM  Illumina Reports Financial Results for Second Quarter of Fiscal Year 2018 Business Wire
03:00PM  Illumina, Inc. to Host Earnings Call ACCESSWIRE
07:22AM  Illumina Q2 Earnings Preview Benzinga
04:38AM  [$$] Illumina shares lit up by earnings beat, outlook raise Financial Times
Jul-27-18 05:57PM  Here's Why Pacific Biosciences Tumbled 10% Today Motley Fool
09:59AM  Why Earnings Season Could Be Great for Illumina (ILMN) Zacks
Jul-26-18 09:59AM  The Zacks Analyst Blog Highlights: Illumina, Ultragenyx Pharmaceutical, Xenon Pharmaceuticals, Vanda Pharmaceuticals and Pharming Group Zacks
Jul-25-18 12:24PM  AbbVie Secures FDA Approval for Endometriosis Drug Elagolix Zacks
12:10PM  Thermo Fisher (TMO) Beats on Q2 Earnings, Ups '18 EPS View Zacks
09:16AM  3 Big Questions for Illumina When It Reports Q2 Earnings Motley Fool
07:58AM  Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions Zacks
Jul-24-18 12:00PM  AstraZeneca Sells Atacand's European Rights to Cheplapharm Zacks
11:57AM  Allergan's Depression Candidate Gets Fast Track Designation Zacks
07:50AM  Initiating Free Research Reports on Intuitive Surgical and Three Other Medical Supplies Equities ACCESSWIRE
Jul-23-18 09:56AM  Can Solid Overall Growth Drive Illumina's (ILMN) Q2 Earnings? Zacks
Jul-19-18 09:21AM  Karyopharm Initiates NDA Submission Process for Selinexor Zacks
Jul-18-18 05:57PM  J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod Zacks
06:59AM  Biotech's Coming Back to Life: Cramer's 'Off the Charts'
03:39AM  J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised) Zacks
Jul-17-18 07:01PM  Cramer's charts suggest big-name biotech stocks Gilead an... CNBC Videos
06:45PM  Cramer's charts suggest big-name biotech stocks Gilead and Celgene have more room to run CNBC
04:04PM  J&J's (JNJ) Phase III Study for Invokana Halted Earlier Zacks
09:40AM  J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised) Zacks
Jul-16-18 08:12AM featured highlights include: Lululemon, Sirius XM, Nutrisystem and Illumina Zacks
Jul-13-18 11:47AM  4 Best Efficient Stocks to Add to Your Portfolio InvestorPlace
Jul-12-18 09:30AM  Has Illumina (ILMN) Outpaced Other Medical Stocks This Year? Zacks
08:37AM  Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial Benzinga
Jul-11-18 08:30AM  Why Aptose Biosciences (APTO) Could Be Positioned for a Slump Zacks
Jul-10-18 04:30PM  Illumina to Announce Second Quarter 2018 Financial Results on Monday, July 30, 2018 Business Wire
Jul-06-18 09:52AM  Here's Why Illumina Stock Has Gained 28.3% in 2018 (So Far) Motley Fool
07:47AM  Zacks Industry Outlook Highlights: Amgen, ANI and Illumina Zacks
Jul-03-18 03:27PM  Alkermes' Aristada Initio Approved by FDA for Schizophrenia Zacks
03:22PM  Roche's Breast Cancer Study Meets Co-Primary Endpoint Zacks
Jun-29-18 01:38PM  The Human Genome Project: At the Root of a Healthcare Revolution Motley Fool
09:48AM  How Healthcare's Changed in the Past 25 Years, Plus What's Next Motley Fool
Jun-27-18 09:45AM  AMGN or ILMN: Which Is the Better Value Stock Right Now? Zacks
09:06AM  Genomics Market Gains Momentum: 3 DNA Stocks in Focus Zacks
Jun-26-18 02:44PM  Illumina's Pullback Looks Like a Buying Opportunity for Further Gain
09:30AM  Is Illumina (ILMN) Outperforming Other Medical Stocks This Year? Zacks
Jun-25-18 10:00AM  Illumina Inc (NASDAQ:ILMN): Time For A Financial Health Check Simply Wall St.
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, agrigenomics, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. The company has a strategic partnership with Loxo Oncology, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and strategic collaboration with Bristol-Myers Squibb Company. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ronaghi MostafaSr VP & CTOAug 10Option Exercise37.0410,000370,40080,805Aug 14 04:07 PM
Ronaghi MostafaSr VP & CTOAug 10Sale331.3910,0003,313,86170,805Aug 14 04:07 PM
OSTADAN OMEADEVP Ops, Products, StrategyAug 02Sale320.701,334427,81424,484Aug 06 08:11 PM
Stapley MarcEVP Strategy & Corp DevelopmtAug 02Sale324.801,000324,7987,516Aug 06 08:10 PM
deSouza Francis APresident and CEOAug 01Sale327.412,100687,55576,535Aug 03 03:03 PM
EPSTEIN ROBERT SDirectorJul 23Sale311.15500155,5756,139Jul 24 07:21 PM
deSouza Francis APresident and CEOJul 12Sale300.003,300990,00078,635Jul 13 02:39 PM
Ronaghi MostafaSr VP & CTOJul 10Option Exercise37.047,500277,80078,496Jul 12 07:39 PM
Ronaghi MostafaSr VP & CTOJul 10Sale288.897,5002,166,70170,996Jul 12 07:39 PM
deSouza Francis APresident and CEOJul 02Sale276.142,100579,88782,271Jul 03 06:20 PM
EPSTEIN ROBERT SDirectorJun 21Sale288.45500144,2256,639Jun 22 07:12 PM
Ronaghi MostafaSr VP & CTOJun 11Option Exercise28.4510,500298,72581,496Jun 13 06:21 PM
Stapley MarcEVP Strategy & Corp DevelopmtJun 11Sale285.181,446412,3648,516Jun 13 06:24 PM
Ronaghi MostafaSr VP & CTOJun 11Sale284.8310,5002,990,75970,996Jun 13 06:21 PM
OSTADAN OMEADEVP Ops, Products, StrategyJun 01Sale274.611,335366,60425,818Jun 04 08:57 PM
deSouza Francis APresident and CEOJun 01Sale272.912,100573,10784,371Jun 04 08:54 PM
EPSTEIN ROBERT SDirectorMay 21Sale271.00500135,5006,588May 22 05:25 PM
EASTHAM KARINDirectorMay 21Sale269.801,000269,80212,288May 22 05:23 PM
Ronaghi MostafaSr VP & CTOMay 16Option Exercise28.4510,000284,50080,996May 18 07:39 PM
Ronaghi MostafaSr VP & CTOMay 16Sale267.7110,0002,677,13570,996May 18 07:39 PM
FLATLEY JAY TDirectorMay 14Sale268.001,460391,2804,000May 16 09:40 PM
deSouza Francis APresident and CEOMay 14Sale268.632,100564,12486,471May 16 09:37 PM
OSTADAN OMEADEVP Ops, Products, StrategyMay 02Sale242.601,314318,77627,153May 04 06:53 PM
BOWMAN A BLAINEDirectorMay 01Option Exercise55.143,000165,42619,868May 03 06:23 PM
BOWMAN A BLAINEDirectorMay 01Sale241.453,000724,33616,868May 03 06:23 PM
Van Oene MarkSVP Chief Commercial OfficerApr 12Sale238.481,400333,87212,217Apr 13 07:30 PM
Dadswell CharlesSr VP & General CounselApr 03Sale230.9111626,7867,875Apr 04 07:32 PM
BOWMAN A BLAINEDirectorApr 02Option Exercise44.513,000133,53019,868Apr 04 07:29 PM
BOWMAN A BLAINEDirectorApr 02Sale230.133,000690,38316,868Apr 04 07:29 PM
ARNOLD FRANCESDirectorMar 15Sale252.2625063,06510,189Mar 15 07:56 PM
ARNOLD FRANCESDirectorMar 08Sale241.5025060,37510,439Mar 08 07:50 PM
Stapley MarcEVP Strategy & Corp DevelopmtMar 06Sale233.642,000467,28813,787Mar 08 07:45 PM
EASTHAM KARINDirectorMar 05Option Exercise71.092,000142,18015,288Mar 06 07:17 PM
EASTHAM KARINDirectorMar 05Sale229.372,000458,73513,288Mar 06 07:17 PM
Dadswell CharlesSr VP & General CounselMar 05Sale227.1714532,9407,991Mar 06 07:13 PM
OSTADAN OMEADEVP Ops, Products, StrategyMar 02Sale222.661,329295,91628,467Mar 05 09:03 PM
BOWMAN A BLAINEDirectorMar 01Option Exercise44.513,000133,53019,868Mar 05 08:12 PM
BOWMAN A BLAINEDirectorMar 01Sale227.013,000681,02816,868Mar 05 08:12 PM
EPSTEIN ROBERT SDirectorFeb 28Sale231.2525057,8137,088Mar 02 07:06 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 16Sale228.851,408322,22113,617Feb 20 09:26 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 15Option Exercise0.002,124015,760Feb 20 09:26 PM
Stapley MarcEVP Strategy & Corp DevelopmtFeb 15Option Exercise0.006,257032,430Feb 20 09:23 PM
Ronaghi MostafaSr VP & CTOFeb 15Option Exercise0.004,740072,785Feb 20 09:18 PM
OSTADAN OMEADEVP Ops, Products, StrategyFeb 15Option Exercise0.006,257032,355Feb 20 09:16 PM
FLATLEY JAY TDirectorFeb 15Option Exercise0.0026,5420413,706Feb 20 09:13 PM
deSouza Francis APresident and CEOFeb 15Option Exercise0.0010,238092,990Feb 20 09:10 PM
Dadswell CharlesSr VP & General CounselFeb 15Option Exercise0.003,79209,455Feb 20 09:07 PM
Stapley MarcEVP Strategy & Corp DevelopmtFeb 06Sale216.872,000433,74126,052Feb 08 06:23 PM
Dadswell CharlesSr VP & General CounselFeb 05Sale221.451,610356,5355,581Feb 05 07:07 PM
BOWMAN A BLAINEDirectorFeb 01Option Exercise44.513,000133,53019,868Feb 05 07:05 PM
BOWMAN A BLAINEDirectorFeb 01Sale230.823,000692,44816,868Feb 05 07:05 PM
EPSTEIN ROBERT SDirectorJan 29Option Exercise51.171,00051,1708,588Jan 30 08:36 PM
EPSTEIN ROBERT SDirectorJan 29Sale244.181,250305,2257,338Jan 30 08:36 PM
Stapley MarcEVP Strategy & Corp DevelopmtJan 17Sale242.332,000484,66728,315Jan 18 07:01 PM
FLATLEY JAY TDirectorJan 16Sale243.7215,0003,655,763437,899Jan 18 06:50 PM
Dadswell CharlesSr VP & General CounselJan 03Sale224.5014532,5537,411Jan 04 06:53 PM
FLATLEY JAY TDirectorJan 02Sale223.4020,0004,468,090452,899Jan 03 09:16 PM
EPSTEIN ROBERT SDirectorDec 29Option Exercise51.171,00051,1708,838Jan 02 08:36 PM
EPSTEIN ROBERT SDirectorDec 29Sale217.381,250271,7257,588Jan 02 08:36 PM
FLATLEY JAY TDirectorDec 19Sale215.4820,0004,309,502472,899Dec 21 08:03 PM
FLATLEY JAY TDirectorDec 05Sale212.5520,0004,251,088491,717Dec 07 08:21 PM
Stapley MarcEVP Strategy & Corp DevelopmtDec 04Sale219.882,000439,76427,395Dec 06 05:50 PM
Dadswell CharlesSr VP & General CounselDec 04Sale225.3314532,6736,388Dec 06 05:48 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 01Option Exercise37.043,540131,12226,827Dec 05 05:47 PM
EPSTEIN ROBERT SDirectorDec 01Option Exercise51.171,00051,1709,088Dec 05 05:50 PM
EPSTEIN ROBERT SDirectorDec 01Sale226.551,250283,1887,838Dec 05 05:50 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 01Sale226.913,540803,26723,287Dec 05 05:47 PM
FLATLEY JAY TDirectorNov 21Option Exercise70.8215,0001,062,300531,717Nov 24 05:31 PM
FLATLEY JAY TDirectorNov 21Sale211.3520,0004,227,023511,717Nov 24 05:31 PM
Van Oene MarkSVP Chief Commercial OfficerNov 15Sale206.21183,71211,673Nov 15 08:02 PM
Stapley MarcEVP Strategy & Corp DevelopmtNov 15Sale205.482,000410,95829,395Nov 16 05:58 PM
Van Oene MarkSVP Chief Commercial OfficerNov 13Sale207.781,232255,98511,691Nov 15 08:02 PM
FLATLEY JAY TDirectorNov 07Option Exercise70.8220,0001,416,400536,717Nov 08 07:37 PM
FLATLEY JAY TDirectorNov 07Sale210.5920,0004,211,749516,717Nov 08 07:37 PM
Dadswell CharlesSr VP & General CounselNov 03Sale207.881,609334,4797,217Nov 07 08:45 PM
Stapley MarcEVP Strategy & Corp DevelopmtOct 26Sale206.882,000413,75932,679Oct 30 08:00 PM
FLATLEY JAY TDirectorOct 24Option Exercise70.8220,0001,416,400539,176Oct 26 06:51 PM
FLATLEY JAY TDirectorOct 24Sale210.4320,0004,208,568519,176Oct 26 06:51 PM
Van Oene MarkSVP Chief Commercial OfficerOct 12Sale207.211,250259,01313,929Oct 13 05:31 PM
FLATLEY JAY TDirectorOct 10Option Exercise70.8220,0001,416,400539,176Oct 12 07:20 PM
FLATLEY JAY TDirectorOct 10Sale203.2720,0004,065,386519,176Oct 12 07:20 PM
Dadswell CharlesSr VP & General CounselOct 03Sale202.2314529,3238,826Oct 05 05:35 PM
FLATLEY JAY TDirectorSep 26Option Exercise70.8220,0001,416,400539,176Sep 28 07:01 PM
FLATLEY JAY TDirectorSep 26Sale200.1620,0004,003,138519,176Sep 28 07:01 PM
Van Oene MarkSVP Chief Commercial OfficerSep 12Option Exercise29.445,838171,87124,908Sep 14 06:05 PM
FLATLEY JAY TDirectorSep 12Option Exercise70.8220,0001,416,400539,176Sep 14 06:08 PM
FLATLEY JAY TDirectorSep 12Sale211.1120,0004,222,121519,176Sep 14 06:08 PM
Van Oene MarkSVP Chief Commercial OfficerSep 12Sale211.339,7292,056,03415,179Sep 14 06:05 PM
Ronaghi MostafaSr VP & CTOSep 07Option Exercise44.3820,000887,60086,725Sep 08 05:41 PM
Ronaghi MostafaSr VP & CTOSep 07Sale210.0020,0004,200,00066,725Sep 08 05:41 PM
Stapley MarcEVP & Chief Administrative OfcSep 05Sale205.932,000411,85734,679Sep 07 07:19 PM
Dadswell CharlesSr VP & General CounselSep 05Sale205.7114529,8288,971Sep 07 07:17 PM
Bouchard MichelChief Accounting OfficerAug 31Sale202.384,774966,17010,387Sep 01 05:34 PM
Bouchard MichelChief Accounting OfficerAug 30Sale200.00616123,20015,161Sep 01 05:34 PM
FLATLEY JAY TDirectorAug 29Option Exercise70.8220,0001,416,400539,176Aug 30 07:58 PM
FLATLEY JAY TDirectorAug 29Sale194.9320,0003,898,692519,176Aug 30 07:58 PM
FLATLEY JAY TDirectorAug 28Sale197.392,540501,370140Aug 30 07:58 PM